After a number of positive referals, Sound Bioventures decided to hire Andulf Advokater with Anders Apell and Ulf Edebrink, as their legal representatives. Anders and Ulf where part of founding Andulf Advokater, back in 2004, and specializes in private equity, venture capital and real estate fund formation. Johan Kördel commented: “Others had told us that Anders and Ulf have superb and strategic legal minds – Boy can we underwrite that! We are so happy to have them on our side. Experienced and efficient – they cut to the chase”
Sound Bioventures Works with Andulf Advokater
Earthquakes, investing in drugs, and how to be decent in Venture Capital.
Sound Bioventures’ Managing Partner Johan Kördel was recently interviewed by Jonas Söderström from BioStock for the latest episode of their Health and Wealth podcast series. The discussion included Johan’s journey from scientist to seasoned life science investor, the importance of risk management, why a portfolio approach is key when you invest in ...
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Stockholm, Sweden and Washington D.C., USA – 17 April 2024 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic vi ...
Beyond fundraising: how do venture capitals build early-stage biotechs?
It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant role in building the company with its founders. To better understand the dynamic between biotech startups and VCs, we talked to Johan […]
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m ...